← Back to Dashboard
Litigation Stage Tracker
Active FilingEmerging
Formation
Active Litigation
Maturation
<45
45–55
55–70
70+
Zantac / Ranitidine
ClosedFILINGMDL 2924Pharma
2,100+
Total Cases
Causation
Plaintiffs alleged ranitidine is inherently unstable and converts to N-Nitrosodimethylamine (NDMA), a probable human carcinogen, at body temperature and during storage. FDA requested withdrawal of all ranitidine products in April 2020. However, Judge Rosenberg in S.D. Fla. excluded all six plaintiffs' general causation experts under Daubert in December 2022, finding their methodologies unreliable.
Defendants
| Entity | Role | Note |
|---|---|---|
| GlaxoSmithKline (GSK) | Original Manufacturer | Developed and first marketed Zantac — primary defendant |
| Sanofi | Manufacturer/Marketer | Marketed OTC Zantac in the US |
| Boehringer Ingelheim | Former Marketer | Held Zantac marketing rights during key period |
| Pfizer Inc. | Manufacturer | Manufactured and marketed Zantac — acquired rights through Warner-Lambert |
Litigation Timeline
Apr 2020
FDA requests market withdrawal of all ranitidine products
Dec 2022
Judge Rosenberg excludes all plaintiffs' general causation experts (Daubert)
2023
Mass dismissal of federal cases following Daubert ruling
2024-2026
Limited state court proceedings continue in Delaware, California
Intelligence Signals
Courtcourt
Uber Technologies, Inc. v. Express Digital Services, LLC
Courtcourt
Lott v. Health Gorilla, Inc.
Courtcourt
Schmidtka v. Boehringer Ingelheim Pharmaceuticals, Inc.
Courtcourt
Reynolds v. Unknown Names of Manufacturer or Responsible Individuals
Key Facts
- Status
- active
Geographic Exposure
·S.D. Fla. (MDL 2924, Judge Rosenberg — largely dismissed)
·Delaware Superior Court (state cases survive)
·California (state cases under different evidentiary standard)
·Limited state court activity in select jurisdictions
Eligibility Criteria
- ✓Used Zantac (ranitidine) regularly for extended period
- ✓Diagnosed with bladder, stomach, esophageal, liver, or pancreatic cancer
- ✓Used product before FDA withdrawal in April 2020
- ✓Note: Federal claims largely barred after Daubert ruling — state court claims may still be viable